Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Allarity Therapeutics

Sangamo Therapeutics

Clover Health Investments

Helius Medical Technologies

Nektar Therapeutics

Vyne Therapeutics

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.

7 Sorry Pharma Stocks to Sell in April Before It's Too Late

After recently reporting strong clinical data, Novavax (NASDAQ: NVAX ) has tremendous opportunities in front of it. More specifically, the company's coronavirus booster and its coronavirus-flu combination vaccine can become huge revenue generators.

Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months

Novavax (NASDAQ: NVAX ) stock is on the move Wednesday despite a lack of news from the vaccine company. There's no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the company's stock is moving today.

Why Is Novavax (NVAX) Stock Moving Today?

Leadership revisions open potential for much-needed performance upgrade. Novavax is marshaling its best efforts to execute on a new designated variant.

Novavax: The Dangerous Allure Of A Promising New Start

GAITHERSBURG, Md. , April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.

Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

Pinterest

Pinterest is performing decently despite headwinds, and it has massive opportunities ahead. Novavax's hopes are fading away as the coronavirus vaccine market shrinks.

1 Stock to Buy and 1 to Avoid Before the Next Bull Market

Carvana

First Republic

Lucid Group

Lyft

Upstart Holdings

WeWork

‘Fallen angel' stocks, or stocks that have fallen far from their past highs, can be tempting as possible contrarian buys. Yet while there are sometimes diamonds in the rough among these names, for the most part, it's best to consider them stocks to sell.

7 ‘Fallen Angel' Stocks to Sell Before They Plummet Again

Novavax is doubtful whether it can keep the lights on through the next 12 months. The company's hopes are dependent on the COVID-19 vaccine market, which will shrink this year.

1 Growth Stock With 741% Upside, According to Wall Street

Bed Bath & Beyond

Design Therapeutics

Silvergate Capital Corp

Tattooed Chef

Short squeeze stocks are the talk of Wall Street at the moment. As the banking crisis continues to unfold, some investors are seeking refuge by betting against many well-known losers — and reaping tremendous gains.

Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze

Peloton

Riot Blockchain

We've already seen valuations drop in 2022, as investors priced in an economic slowdown. However, it's unclear whether a full-on market crash is being priced into equity markets right now.

3 Stocks That Won't Survive a Major Market Crash

The company now has a vacancy at the top of its research and development department. Greg Glenn will officially vacate his post on March 31.

Why Novavax Stock Slipped on Thursday

Novavax missed out on the first big wave of vaccine demand -- and that's weighed on the company's progress. Now, the biotech is taking steps to improve its chances of success in a post-pandemic world.

1 Green Flag and 1 Red Flag for Novavax

Is Novavax stock a sell after the company says it has "substantial doubt" about its future? Is NVAX stock a sell right now?

Is Novavax Stock A Sell After Expressing 'Substantial Doubt' About Its Future?

Tilray Brands

Falling stock prices can present bargains, but not every fallen stock is a good buy. Tilray's vision is compelling, and its price is cheap, though its margins remain weak.

2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully So

Moderna

Pfizer

During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

Novavax's COVID-19 vaccine hasn't made it profitable. The business is now struggling to stay afloat.

This Growth Stock Is Down 90%. Is It Time to Sell or Buy?

Novavax isn't going to rally if there's a bull market, as it has severe problems. It expects to cut costs, and its leaders think it could realistically close down.

1 Stock You Need to Sell Before the Next Bull Market

Novavax is facing declining vaccine demand and higher costs. At the same time, the company is working on a combined flu/coronavirus vaccine candidate that could stand out in a post-pandemic market.

Novavax Stock: Bear vs. Bull

Novavax reported an unprofitable 2022 despite strong revenue from its COVID-19 vaccine. The company's rate of cash burn has been sustainable, but that could change this year.

Novavax Just Dropped a Bombshell on Investors: Even Management Is Questioning Its Future

GAITHERSBURG, Md. , March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.

Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference

While the major equity indices finally printed a solid performance to close out a rough week, biotechnology firm Novavax (NASDAQ: NVAX ) raised eyebrows of its own. After mounting pressure from bearish traders over significant viability concerns, NVAX stock initially popped up 12%.

Why Is Novavax (NVAX) Stock Up 12% Today?

After a spectacular 2020 performance, Novavax's shares have plummeted.

Should You Give Up on Novavax?

Investors were disappointed yet again with the vaccine company's quarterly earnings and forward guidance.

Why Novavax Stock Was Down in the Dumps This Week

Novavax (NASDAQ: NVAX ) stock is down more than 25% today after the biotechnology company reported fourth-quarter earnings and raised doubts about its ability to continue as a “going concern.” The company noted the following in the report: “While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration.

5 Investors Still Betting Big on Novavax (NVAX) Stock

Covid-19 vaccine developer Novavax, one of the stars of the early pandemic, issued a going concern warning which sent its stock reeling. It warned that “substantial doubt exists regarding our ability to operate as a going concern” through the next year.

News for Novavax Stock (NVAX)